Details for Patent: 10,953,003
✉ Email this page to a colleague
Which drugs does patent 10,953,003 protect, and when does it expire?
Patent 10,953,003 protects XOLREMDI and is included in one NDA.
This patent has thirty-four patent family members in eleven countries.
Summary for Patent: 10,953,003
Title: | Methods for treating cancer |
Abstract: | The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity. |
Inventor(s): | Ragan Paula Marie, Arbeit Robert D., Crowley Kieran James |
Assignee: | |
Application Number: | US16061974 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,953,003
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,953,003
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 3008272 | ⤷ Sign Up | |||
Canada | 3008279 | ⤷ Sign Up | |||
Canada | 3009176 | ⤷ Sign Up | |||
Canada | 3010617 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |